← Back to Clinical Trials
Recruiting Phase 3 NCT04670666

Efficacy and Safety of Madalena Association in the Treatment of Type II Diabetes Mellitus

Trial Parameters

Condition Type 2 Diabetes Mellitus
Sponsor EMS
Study Type INTERVENTIONAL
Phase Phase 3
Enrollment 270
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-11-18
Completion 2026-07
Interventions
MADALENA ASSOCIATIONMETFORMINEMPAGLIFLOZIN + LINAGLIPTIN

Brief Summary

The purpose of this study is to evaluate the efficacy and safety of Madalena association in the treatment of type 2 diabetes mellitus.

Eligibility Criteria

Inclusion Criteria: * Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; * Participants with 18 years of age or greater; * Participants presenting the diagnosis of type II diabetes mellitus, and who did not reach the therapeutic goals of HbA1c with previous dietary, physical exercise guidance and at least 3 months with two anti-hyperglycemic agents (dual therapy); * HbA1c ≥ 7,5% and ≤ 10,5% and fasting blood glucose \> 100 mg/dL at the screening visit; * BMI (body mass index) \> 19 Kg/m2 and ≤ 45 Kg/m2. Exclusion Criteria: * Any clinical and laboratory findings that, in the judgment of the investigator, may interfere with the safety of research participants; * History of alcohol abuse or illicit drug use; * Participation in a clinical trial in the year prior to this study; * Pregnancy or risk of pregnancy and lactating patients; * Known hypersensitivity to the formula components used during the clinical trial; *

Related Trials